Hip Osteoarthritis stem cell therapy — your questions answered (2026)

About stem cell therapy for Hip Osteoarthritis

Hip osteoarthritis (OA) involves progressive structural and biological changes in cartilage, bone and synovium that can cause pain, stiffness and reduced function. Mesenchymal stromal cells (MSCs), extracellular vesicles and other biological approaches are being studied for proposed anti-inflammatory or tissue-signalling effects. Intra-articular delivery places a product in the joint but does not establish cartilage regeneration or slower disease progression. Cell or exosome injection is not standard disease-modifying hip-OA care. The registry table on this page lists relevant studies and their current recruitment status.

The evidence for Hip Osteoarthritis

Human hip-OA studies of cell and related biological products vary by disease severity, product, dose, comparator, imaging method, rehabilitation and endpoint. Pain or function changes do not establish cartilage repair, and uncontrolled imaging changes cannot prove slower progression or avoidance of joint replacement. No pooled response rate is published here because the studies are too heterogeneous for a single figure to be meaningful. The registered studies and their own prespecified endpoints are listed in the registry table on this page.

Private investigational hip cell or exosome injections can involve separate charges for image guidance, imaging, repeat administration, rehabilitation, travel and treatment of complications. Prices do not indicate regulatory approval, cartilage repair or avoidance of joint replacement, and repeat dosing is not an established standard. Patients should request an itemised written quote and verify sponsor, insurer and patient responsibilities. Evidence-based non-surgical care and indicated surgical assessment must not be delayed.

Can stem cells regrow hip cartilage?

Cell therapy for Hip Osteoarthritis may be offered as an individualised programme, but regulatory status depends on the product, processing, indication and jurisdiction. It is currently investigational. Verify authorisation status, cell source, release testing and clinical evidence for the specific proposal.

Will it delay a hip replacement?

Schedules vary by the exact product, protocol, route, monitoring needs and clinical context. Request the proposed schedule and its evidence before making travel arrangements.

One injection or several?

Eligibility depends on the protocol's inclusion and exclusion criteria and an appropriately qualified clinician's assessment. An online checklist cannot determine candidacy or replace medical advice.

EU cost?

The partner-published indicative range for an Hip Osteoarthritis programme is €3,000–€8,000 for treatment. Request a current written quotation and compare product, dose, visits, inclusions and follow-up before using country ranges as a benchmark.

Sources & further reading

We link primary regulators, registries and peer-reviewed research so you can verify everything yourself — plus the treating clinic's own materials.

• Open clinical trials for Hip Osteoarthritis (ClinicalTrials.gov) ↗
• Peer-reviewed research on PubMed ↗
• ISSCR patient guide — what to ask ↗
• FDA consumer warning on stem-cell therapies ↗
• EMA — advanced-therapy (ATMP) framework ↗

← Back to Hip Osteoarthritis overview · Hip Osteoarthritis cost →